A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

NCT02243280 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
Hepatitis C Virus
HCV

Interventions

DRUG: ABT-493
DRUG: ABT-530

Sponsor

AbbVie